ERBB2 and breast cancer: Second, poorer clinical outcomes are associated with PTEN loss and/or PIK3CA activating mutations, even when treated with TRS, as shown by multiple retrospective investigations of PTEN in tumors from HER2+ metastatic BC patients [26,27].